Literature DB >> 10506189

The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties.

M Dockal1, D C Carter, F Rüker.   

Abstract

In an attempt to systematically dissect the ligand binding properties of human serum albumin (HSA), the gene segments encoding each of its three domains were defined based on their conserved homologous structural motifs and separately cloned into a secretion vector for Pichia pastoris. We were able to establish a generally applicable purification protocol based on Cibacron Blue affinity chromatography, suggesting that each of the three domains carries a binding site specific for this ligand. Proteins were characterized by SDS-polyacrylamide gel electrophoresis, isoelectric focusing, gel filtration, N-terminal sequencing, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, as well as near- and far-UV CD. In addition to the affinity chromatography ligand Cibacron Blue, binding properties toward hemin, warfarin, and diazepam, each of which represents a standard ligand for HSA, respectively, were investigated by the measurement of induced circular dichroism. Clear experimental evidence is provided here for the location of the primary hemin binding site to be on domain I of HSA, and for the primary diazepam binding site to be on domain III. Further, secondary binding sites were found for hemin to be located on domains II and III, and for diazepam on domain I. The warfarin binding site was located primarily on domain II, while on domain I, a secondary binding site and/or parts of the primary binding site were found.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506189     DOI: 10.1074/jbc.274.41.29303

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  The effects of glycation on the binding of human serum albumin to warfarin and L-tryptophan.

Authors:  K S Joseph; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2010-05-06       Impact factor: 3.935

Review 2.  Overcoming the heme paradox: heme toxicity and tolerance in bacterial pathogens.

Authors:  Laura L Anzaldi; Eric P Skaar
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

3.  Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography.

Authors:  K S Joseph; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-06-01       Impact factor: 3.205

4.  Distributions of experimental protein structures on coarse-grained free energy landscapes.

Authors:  Kannan Sankar; Jie Liu; Yuan Wang; Robert L Jernigan
Journal:  J Chem Phys       Date:  2015-12-28       Impact factor: 3.488

5.  Truncated human serum albumin retains general anaesthetic binding activity.

Authors:  Renyu Liu; Jinsheng Yang; Chung-Eun Ha; Nadhipuram V Bhagavan; Roderic G Eckenhoff
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

6.  Denaturation mechanism of BSA by urea derivatives: evidence for hydrogen-bonding mode from fluorescence tools.

Authors:  R Kumaran; P Ramamurthy
Journal:  J Fluoresc       Date:  2011-02-02       Impact factor: 2.217

7.  Adsorption of human serum albumin on the chrysotile surface: a molecular dynamics and spectroscopic investigation.

Authors:  Roberto Artali; Antonio Del Pra; Elisabetta Foresti; Isidoro Giorgio Lesci; Norberto Roveri; Piera Sabatino
Journal:  J R Soc Interface       Date:  2008-03-06       Impact factor: 4.118

Review 8.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

Review 9.  One ring to rule them all: trafficking of heme and heme synthesis intermediates in the metazoans.

Authors:  Iqbal Hamza; Harry A Dailey
Journal:  Biochim Biophys Acta       Date:  2012-05-08

10.  Identification of high affinity fatty acid binding sites on human serum albumin by MM-PBSA method.

Authors:  Shin-ichi Fujiwara; Takashi Amisaki
Journal:  Biophys J       Date:  2007-09-07       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.